Obstructive sleep apnoea syndrome as a risk factor for hypertension: population study
By P. Lavie, P. Herer, V. Hoffstein. British medical journal, 2000
1,036 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine, Experimental and Cognitive Psychology, Physiology
View Paper: https://www.semanticscholar.org/paper/29c9f02f06d93aa3e944f097e6b9e5992ab5eeed
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
In Experimental and Cognitive Psychology
In Physiology
Citations in the corpus
- 2007 ESH‐ESC Guidelines for the management of arterial hypertension (2007, background): “(738) The syndrome may contribute to the elevated pressure in a large proportion of hypertensive patients, (817,818) the pressor effect being possibly generated by an impairment of reflex cardiovascular regulation and endothelial dysfunction.”
- Epidemiology of obstructive sleep apnea: a population health perspective. (2002, background): “Grote and coworkers (105) and Lavie and coworkers (106) found significant associations between polysomnography-assessed OSA and increased blood pressure or the occurrence of hypertension in large samples of sleep clinic patients.”
- Increased adhesion molecules expression and production of reactive oxygen species in leukocytes of sleep apnea patients. (2002, background): “We showed that: ( 1 ) Sleep apnea syndrome is associated with increased expression of two adhesion molecules, CD15 and CD11c in monocytes.”
- Obstructive sleep apnea-hypopnea and related clinical features in a population-based sample of subjects aged 30 to 70 yr. (2001, background): “In our study, however, the odds ratio of hypertension did not increase by AHI category, which is in contrast to data found in patients referred to the sleep clinic with suspected sleep apnea syndrome (33).”
- Association Between Treated and Untreated Obstructive Sleep Apnea and Risk of Hypertension (2012, neutral): “Lowering-lipid use 22 (7) 24 (9) 21 (11) 6 (11) 18 (13) 24 (10) 77 (13)”